SCHEMBL12697202

SCHEMBL12697202

Cc1ccc(N2CCN(S(C)(=O)=O)CC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.51
LMNA P02545 1/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
RORC P51449 2/20 0.47
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ACVR1B P36896 1/20 0.44
TGFBR1 P36897 1/20 0.44
ACVR1 Q04771 1/20 0.44
SMO Q99835 2/20 0.44
GPR119 Q8TDV5 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21245746 0.83 GCKR (0.52) LMNAMEN1KMT2ARORCMAPT
SCHEMBL12695035 0.80 RORC (0.50) LMNAMEN1KMT2ARORCMAPT
SCHEMBL24681795 0.79 GPR119 (0.46) SMOGPR119
SCHEMBL24107591 0.79 MAPT (0.49) LMNAMEN1KMT2ARORCMAPT
SCHEMBL21245689 0.78 MAPT (0.65) LMNAKMT2AMAPTPOLBRAB9A
SCHEMBL82236 0.78 MAPT (0.50) MEN1KMT2AMAPTRAB9AKDM4E
SCHEMBL82680 0.78 MEN1 (0.69) LMNAMEN1KMT2AMAPTPOLB
SCHEMBL9853734 0.77 MAPT (0.50) MEN1KMT2AMAPTPOLBRAB9A
SCHEMBL24107471 0.76 HRH3 (0.52) MEN1KMT2AMAPTPOLBRAB9A
SCHEMBL9881494 0.75 MAPT (0.53) MEN1KMT2AMAPTPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022236256-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2022-11-10 WO disclosed
WO-2022236253-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2022-11-10 WO disclosed
US-20120245136-A1 CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2012-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245136-A1 CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, KCNJ1, KCNC1 CHEK1 2903/4885LMNA 1347/4885MEN1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.